NATIONAL SURVEY: Biosimilars' Savings Appeal, But Patient Knowledge Lags

A new survey from the Biologics Prescribers Collaborative gauges patients' understanding of biologics and biosimilars and explores what motivates patients to switch medications

WASHINGTON, Aug. 8, 2023 /PRNewswire/ -- A national survey from the Biologics Prescribers Collaborative reveals that about half of people who have taken an innovator biologic or follow-on biosimilar report knowing only "a little" about the medications. Cost savings are the factor most likely to motivate patients to switch from an innovator biologic to a biosimilar.

KEY FINDINGS

Patient Knowledge Gap
While 46% of survey respondents have had been receiving an innovator biologic or biosimilar for between one and five years, respondents varied in how much they knew about the medications.

• 50% reported knowing "a little" about biologics and biosimilars.
• 36% did not know that biosimilars are generally less expensive than their innovator biologic counterparts.
• 55% did not know that interchangeable biosimilars can be swapped with their innovator biologic at the pharmacy level without the prescribing clinician's involvement.
• 68% said they'd turn to their doctor for more information.

Patient Confidence and Trust
Respondents were largely confident in biosimilars, the treatments' safety and their effectiveness. They also agreed (85%) that biosimilars benefit the health care system.

• 95% reported trusting innovator biologics, while 91% said they trust biosimilars.
• The majority said biosimilars are as safe (74%) and effective (71%) as their innovator biologic.
• 70% agreed that biosimilars save patients money.

Patient Experience
Two-thirds (66%) of respondents had taken a biosimilar, and the majority (84%) of those who'd taken a biosimilar had switched from an innovator biologic.

• 43% cited their clinician's recommendation as the reason for switching from a biologic to a biosimilar.
• 41% said the biosimilar worked better, 33% said the biologic worked better and 22% didn't perceive a difference.

Cost savings are the primary factor that would lead patients to consider switching. Nearly half (49%) of surveyed patients said they would consider switching if the biosimilar would save them money.

READ: Patient Choice: National Survey on Innovator Biologics and Biosimilars

The Biologics Prescribers Collaborative is a coalition that aims to ensure that sound policies are in place to promote the safest possible use of all biologics, including biosimilars, for all patients.

SOURCE Biologics Prescribers Collaborative

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED